Anupam Rama
Stock Analyst at JP Morgan
(3.17)
# 1,048
Out of 4,829 analysts
262
Total ratings
39.62%
Success rate
1.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.60 | +508.70% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $35.11 | +233.24% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $115.71 | +59.02% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $34.17 | +46.33% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $10.70 | +283.18% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $29.24 | +74.42% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $2.76 | +298.55% | 7 | Mar 13, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $39 → $34 | $6.45 | +427.13% | 4 | Mar 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $36 → $42 | $19.62 | +114.07% | 11 | Mar 5, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $77 → $71 | $21.71 | +227.04% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $17.30 | +212.14% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $20.02 | +119.78% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $7.71 | +133.46% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $5.08 | +333.07% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.62 | +211.85% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $21 | $4.81 | +336.59% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $5.99 | +184.04% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.75 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $26.06 | +53.49% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $69.85 | +78.95% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.72 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $46.26 | +47.00% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $17.42 | +278.87% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $6.57 | +52.21% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.29 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $36.27 | +382.49% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.93 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $1.60 | +712.50% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.36 | +2,400.00% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.77 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.34 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $7.31 | +3,319.97% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.33 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $31.70 | +82.99% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $8.98 | +33.63% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.09 | +627.63% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $42.95 | +28.06% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.38 | +1,928.99% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.32 | +97.66% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.43 | +10,369.99% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $11.41 | +136.63% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $6.67 | +500.15% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $251.15 | -45.45% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $3.89 | +902.57% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $5.95 | +706.72% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.41 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.86 | +1,995.95% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.61 | +1,763.35% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $44.23 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.71 | - | 2 | Jul 21, 2017 |
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.60
Upside: +508.70%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $35.11
Upside: +233.24%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $115.71
Upside: +59.02%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $34.17
Upside: +46.33%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $10.70
Upside: +283.18%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $29.24
Upside: +74.42%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $2.76
Upside: +298.55%
Day One Biopharmaceuticals
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.45
Upside: +427.13%
AnaptysBio
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $19.62
Upside: +114.07%
Vera Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $21.71
Upside: +227.04%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $17.30
Upside: +212.14%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $20.02
Upside: +119.78%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $7.71
Upside: +133.46%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $5.08
Upside: +333.07%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $9.62
Upside: +211.85%
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $4.81
Upside: +336.59%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $5.99
Upside: +184.04%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.75
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $26.06
Upside: +53.49%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $69.85
Upside: +78.95%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $46.26
Upside: +47.00%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $17.42
Upside: +278.87%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $6.57
Upside: +52.21%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $36.27
Upside: +382.49%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.93
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $1.60
Upside: +712.50%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.36
Upside: +2,400.00%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.77
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.34
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $7.31
Upside: +3,319.97%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $31.70
Upside: +82.99%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $8.98
Upside: +33.63%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.09
Upside: +627.63%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $42.95
Upside: +28.06%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.38
Upside: +1,928.99%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.32
Upside: +97.66%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.43
Upside: +10,369.99%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $11.41
Upside: +136.63%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $6.67
Upside: +500.15%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $251.15
Upside: -45.45%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $3.89
Upside: +902.57%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $5.95
Upside: +706.72%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $9.41
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.86
Upside: +1,995.95%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.61
Upside: +1,763.35%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $44.23
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.71
Upside: -